Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3T Stroke-III tenecteplase versus alteplase in hyperacute ischemic stroke
CTR20222248Phase 3Active
- Sponsor
- Shimao Tianjie Pharmaceutical
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Shimao Tianjie Pharmaceutical. Started Oct 2022; status: active.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20222248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222248.